Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Agile Therap (AGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,178
  • Shares Outstanding, K 43,743
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,780 K
  • 60-Month Beta 0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.09
  • Low Estimate -0.13
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.20 +10.83%
on 05/23/19
1.54 -13.63%
on 04/30/19
-0.14 (-9.52%)
since 04/24/19
3-Month
0.90 +47.78%
on 03/01/19
1.70 -21.76%
on 03/15/19
+0.41 (+44.57%)
since 02/22/19
52-Week
0.23 +478.26%
on 08/13/18
1.70 -21.76%
on 03/15/19
+0.72 (+116.26%)
since 05/24/18

Most Recent Stories

More News
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla(R)

FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019

AGRX : 1.33 (unch)
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla(R)

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla,...

AGRX : 1.33 (unch)
Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at the 2019 RBC Capital Markets Global Healthcare...

AGRX : 1.33 (unch)
Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting

Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla (AG200-15), an investigational, once weekly, low-dose...

AGRX : 1.33 (unch)
Agile Therapeutics: 1Q Earnings Snapshot

PRINCETON, N.J. (AP) _ Agile Therapeutics Inc. (AGRX) on Thursday reported a loss of $4.7 million in its first quarter.

AGRX : 1.33 (unch)
Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences...

AGRX : 1.33 (unch)
Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress

Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla has been selected...

AGRX : 1.33 (unch)
Agile Therapeutics: 4Q Earnings Snapshot

PRINCETON, N.J. (AP) _ Agile Therapeutics Inc. (AGRX) on Tuesday reported a loss of $3.8 million in its fourth quarter.

AGRX : 1.33 (unch)
Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019

AGRX : 1.33 (unch)
Agile Therapeutics to Present at Upcoming Investor Conferences

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer's 29 Annual...

AGRX : 1.33 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AGRX with:

Business Summary

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch...

See More

Key Turning Points

2nd Resistance Point 1.39
1st Resistance Point 1.36
Last Price 1.33
1st Support Level 1.29
2nd Support Level 1.25

See More

52-Week High 1.70
Last Price 1.33
Fibonacci 61.8% 1.14
Fibonacci 50% 0.97
Fibonacci 38.2% 0.79
52-Week Low 0.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar